What is the balance of benefits and harms for lung cancer screening with low-dose computed tomography?

Bradley, Stephen H; Shinkins, Bethany; Kennedy, Mpt

doi:10.1177/0141076821991108

Cited by 5 publications

(2 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25,27 The main concerning harm from screening is the unneeded invasive procedure that entails falsepositive findings. 28,29 The false-positive rate in the NLST in those receiving LDCT was 23.3%. From these false-positive tests, 0.06% experienced a 'major complication after an invasive procedure.…”

Section: Risks and Benefits Of Screeningmentioning

confidence: 97%

Indonesian Society of Respirology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia

Andarini

Syahruddin

Aditya³

et al. 2023

J Respirol Indones

View full text Add to dashboard Cite

Lung cancer is the leading cause of mortality for all cancer globally and in Indonesia. In Indonesia, lung cancer contributes to 12.6% of death of all cancer, making it the number one cause of cancer death, and 8.6% of all cancer incidence in 2018, behind breast, cervical, and colorectal cancer. The total cases per year are expected to almost double from 30,023 in 2018 to 54,983 cases in 2040. Smoking is among the risk factors for lung cancer, after occupational/environmental risk factors, history of lung fibrosis, and family history of cancer. There was a tendency of younger smokers in Indonesia and increased lung cancer incidence and prevalence in the younger population. The median age of lung cancer in Indonesia was younger than in any country, probably due to the younger age of smoking, early onset of carcinogens, asbestos use, and environmental. Lung cancer screening is a voluntary measure to detect lung cancer in the earliest stage, to find cancer at curable disease before symptoms appear in high-risk individuals. Lung cancer early detection is strategies to find cancer earlier after symptoms appear (cough, hemoptysis, dyspnea, chest pain). Low-dose computerized tomography of the thorax (LDCT) screening has been known to reduce lung cancer mortality compared to a chest x-ray (CXR). This Indonesian Society of Respirology consensus statement was aimed to give recommendations on lung cancer screening and early diagnosis in Indonesia.

show abstract

Section: Risks and Benefits Of Screeningmentioning

confidence: 97%

Indonesian Society of Respirology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia

Andarini

Syahruddin

Aditya³

et al. 2023

J Respirol Indones

View full text Add to dashboard Cite

show abstract

“…Computed tomography carries a higher radiation dose and a higher risk of iatrogenic harm than chest radiography, although these risks are still low (table 2). It is also more costly, carries more potential for overdiagnosis, and is frequently less accessible 303132. Although evidence from symptomatic populations is lacking, screening studies show that computed tomography is considerably more sensitive than chest radiography in detecting lung cancer.…”

Section: What Is the Next Investigation?mentioning

confidence: 99%

Investigating suspected lung cancer

Bradley¹,

Bhartia²,

Kennedy³

et al. 2022

BMJ

Self Cite

View full text Add to dashboard Cite

An International Consensus on Actions to Improve Lung Cancer Survival: A Modified Delphi Method Among Clinical Experts in the International Cancer Benchmarking Partnership

et al. 2022

View full text Add to dashboard Cite

Background Research from the International Cancer Benchmarking Partnership (ICBP) demonstrates that international variation in lung cancer survival persists, particularly within early stage disease. There is a lack of international consensus on the critical contributing components to variation in lung cancer outcomes and the steps needed to optimise lung cancer services. These are needed to improve the quality of options for and equitable access to treatment, and ultimately improve survival. Methods Semi-structured interviews were conducted with 9 key informants from ICBP countries. An international clinical network representing 6 ICBP countries (Australia, Canada, Denmark, England, Ireland, New Zealand, Northern Ireland, Scotland & Wales) was established to share local clinical insights and examples of best practice. Using a modified Delphi consensus model, network members suggested and rated recommendations to optimise the management of lung cancer. Calls to Action were developed via Delphi voting as the most crucial recommendations, with Good Practice Points included to support their implementation. Results Five Calls to Action and thirteen Good Practice Points applicable to high income, comparable countries were developed and achieved 100% consensus. Calls to Action include (1) Implement cost-effective, clinically efficacious, and equitable lung cancer screening initiatives; (2) Ensure diagnosis of lung cancer within 30 days of referral; (3) Develop Thoracic Centres of Excellence; (4) Undertake an international audit of lung cancer care; and (5) Recognise improvements in lung cancer care and outcomes as a priority in cancer policy. Conclusion The recommendations presented are the voice of an expert international lung cancer clinical network, and signpost key considerations for policymakers in countries within the ICBP but also in other comparable high-income countries. These define a roadmap to help align and focus efforts in improving outcomes and management of lung cancer patients globally.

show abstract

What is the balance of benefits and harms for lung cancer screening with low-dose computed tomography?

Cited by 5 publications

References 53 publications

Indonesian Society of Respirology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia

Indonesian Society of Respirology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia

Investigating suspected lung cancer

An International Consensus on Actions to Improve Lung Cancer Survival: A Modified Delphi Method Among Clinical Experts in the International Cancer Benchmarking Partnership

Contact Info

Product

Resources

About